Publications by authors named "W Jacot"

Claim this Profile
T
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review-NEW Group (Neutropenic Events Working Group).
Gabriel Antherieu, Vincent Thibaud, Pierre Sesques, William Jacot, Karima Menia

Support Care Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, William Jacot

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.
Fanny Bouteiller, Sophie Gourgou, Michaël Bringuier, Angéline Galvin, Audrey Mailliez, William Jacot

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancer.
Constance Delaby, Anas Al Herk, Christophe Hirtz, William Jacot, Maryline Laigre

BMC Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis